Triad Wealth Partners’s Zomedica Corp. ZOM Stock Holding History

Triad Wealth Partners’s Portfolio ZOM Stock Details ZOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-50	Closed	-$7	–	1008
2024 Q2	$7	Buy	+50	New	+$7	﹤0.01%	998

Other funds holding ZOM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

OPS

Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Triad Wealth Partners's ZOM Position: Q3 2024 in Review

Triad Wealth Partners sold out of Zomedica Corp. (ZOM) in Q3 2024, closing a stake of 50 shares — an estimated $7 sold.

Triad Wealth Partners first reported a position in ZOM in Q2 2024 and held it in 1 quarter. The position peaked at $7 in Q2 2024. 84 funds tracked by Wall St. Rank hold ZOM as of Q3 2024.

Triad Wealth Partners reported no remaining Zomedica Corp. position as of Q3 2024 after selling out during the quarter.
Triad Wealth Partners sold 50 Zomedica Corp. shares in Q3 2024, an estimated $7.
Triad Wealth Partners first reported a position in Zomedica Corp. in Q2 2024 and held it in 1 quarter.
Triad Wealth Partners's Zomedica Corp. position peaked at $7 in Q2 2024.
84 funds tracked by Wall St. Rank held Zomedica Corp. as of Q3 2024.

Based on Triad Wealth Partners's 13F filing for Q3 2024, filed 21 Oct 2024.